Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation

International Journal of Cancer

Volumn 118, Issue 2, 2006, Pages 290-301

  Hiscox, Stephen ^a   Jiang, Wen Go ^b   Obermeier, Kathrin ^a   Taylor, Kathryn ^a   Morgan, Liam ^a   Burmi, Raj ^a   Barrow, Denise ^a   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

catenin; Endocrine resistance; Epidermal growth factor receptor; Epithelial to mesenchymal transition; Invasion

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; HERMES ANTIGEN; LYMPHOID ENHANCER FACTOR 1; MYC PROTEIN; NUCLEAR PROTEIN; SERINE; TAMOXIFEN; THREONINE; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER RESISTANCE; CELL ADHESION; CELL INTERACTION; CELL JUNCTION; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; CYTOPLASM; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYME CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; BETA CATENIN; BREAST NEOPLASMS; CELL ADHESION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PHENOTYPE; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 28844494352     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21355     Document Type: Article

References (71)

1. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer 2002;2:101-12.
2. Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994;32:49-55.
3. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
4. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by sefitinib ("Iressa", ZD1839). Clin Exp Metastasis 2004;21:201-12.
5. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000;36:1607-20.
6. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS. Association of E-cadherin and β-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 2004;35:663-9.
7. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003;94:575-81.
8. Nagafuchi A. Molecular architecture of adherens junctions. Curr Opin Cell Biol 2001;13:600-3.
9. Wong NA, Pignatelli M. β-Catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
10. Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, Dejana E. β-Catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 2004;166:359-67.
11. Muller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp Cell Res 2002;280:119-33.
12. Kim K, Lu Z, Hay ED. Direct evidence for a role of β-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002;26:463-76.
13. Wagenaar RA, Crawford HC, Matrisian LM. Stabilized β-catenin immortalizes colonic epithelial cells. Cancer Res 2001;61:2097-104.
14. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
15. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-305.
16. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999;274:36734-40.
17. Hoschuetzky H, Aberle H, Kemler R. β-Catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375-80.
18. Hazan RB, Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998;273:9078-84.
19. Piedra J, Martinez D, Castano J, Miravet S, Dunach M. de Herreros AG. Regulation of β-catenin structure and activity by tyrosine phosphorylation. J Biol Chem 2001;276:20436-43.
20. Moon HS, Choi EA, Park HY, Choi JY, Chung HW, Kim JI, Park WI. Expression and tyrosine phosphorylation of E-cadherin, β- and γ-catenin, and epidermal growth factor receptor in cervical cancer cells. Gynecol Oncol 2001;81:355-9.
21. Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamoto M, Tamura S, Shibamoto S, Ito F, Monden M. Aberrant expression and phosphorylation of β-catenin in human colorectal cancer. Br J Cancer 1998;77:605-13.
22. Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs 2000;60(Suppl 1):33-42.
23. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
24. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, Mansel RE. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 2003;9:6432-40.
25. Hiscox S, Jiang WG. Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of β-catenin. Anticancer Res 1999;19:509-17.
26. Li H, Pamukcu R, Thompson WJ. β-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 2002;1:621-5.
27. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-86.
28. Morin PJ. β-Catenin signaling and cancer. Bioessays 1999;21:1021-30.
29. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-β-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 2002; 277:22692-8.
30. Takahashi K, Suzuki K, Tsukatani Y. Induction of tyrosine phosphorylation and association of β-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence. Oncogene 1997;15:71-8.
31. Hu P, O'Keefe EJ, Rubenstein DS. Tyrosine phosphorylation of human keratinocyte β-catenin and plakoglobin reversibly regulates their binding to E-cadherin and α-catenin. J Invest Dermatol 2001; 117:1059-67.
32. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A, Dunach M. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate β-catenin Tyr-142 phosphorylation and β-catenin-α- catenin interaction. Mol Cell Biol 2003;23:2287-97.
33. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997;57:2890-5.
34. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
35. Tsatas D, Kanagasundaram V, Kaye A, Novak U. EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci 2002;9:282-8.
36. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000;60:1091-9.
37. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6.
38. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of β-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 1999;81:1392-7.
39. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 2002;36:115-24.
40. Kalogeraki A, Bouros D, Zoras O, Karabekios S, Chalkiadakis G, Stathopoulos E, Siafakas N, Delides GS. E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion. Anticancer Res 2003;23:3367-71.
41. Bankfalvi A, Krassort M, Buchwalow IB, Vegh A, Felszeghy E, Piffko J. Gains and losses of adhesion molecules (CD44, E-cadherin, and β-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002;198:343-51.
42. Li Q, Dashwood WM, Zhong X, Al-Fageeh M, Dashwood RH. Cloning of the rat β-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters. Genomics 2004;83:231-42.
43. Bek S, Kemler R. Protein kinase CKII regulates the interaction of β-catenin with α-catenin and its protein stability. J Cell Sci 2002;115: 4743-53.
44. Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates β-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell 2004;15:2156-63.
45. Rival C, Wever OD, Bruyneel E, Mareel M, Gespach C, Attoub S. Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. Oncogene 2004;23:3317-27.
46. Xu G, Craig AW, Greer P, Miller M, Anastasiadis PZ, Lilien J, Balsamo J. Continuous association of cadherin with β-catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci 2004;117:3207-19.
47. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA, Lee ME. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001;276:17479-83.
48. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 1996;272:1023-6.
49. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004;303:1483-7.
50. Hatsell S, Rowlands T, Hiremath M, Cowin P. β-Catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 2003;8:145-58.
51. Adam L, Vadlamudi RK, McCrea P, Kumar R. Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/β-catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 2001;276:28443-50.
52. Cheon SS, Nadesan P, Poon R, Alman BA. Growth factors regulate β-catenin-mediated TCP-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res 2004;293:267-74.
53. Eger A, Stockinger A, Schaffhauser B, Beug H, Foisner R. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of β-catenin and upregulation of β-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 2000;148:173-88.
54. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent β-catenin transcriptional activity. J Cell Biol 2001;154:1185-96.
55. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R. β-Catenin and TGF-β signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 2004;23: 2672-80.
56. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
57. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
58. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
59. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res 1999;59:1572-7.
60. Mei JM, Hord NG, Winterstein DF, Donald SP, Phang JM. Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated β-catenin-LEF-1 transcription complex in mouse colonic epithelial cells contrasting in Apc. Carcinogenesis 1999;20: 737-40.
61. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96: 1603-8.
62. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999;154:515-23.
63. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-8.
64. Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y, Sanicola M, Salomon DS. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004;201:266-76.
65. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 2004;108:825-32.
66. Marchenko ND, Marchenko GN, Weinreb RN, Lindsey JD, Kyshtoobayeva A, Crawford HC, Strongin AY. β-Catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004; 36:942-56.
67. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000;97:2202-7.
68. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99: 335-45.
69. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-80.
70. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001;98:2598-603.
71. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 2004;10:481-3.